OmniAb to Report First Quarter 2023 Financial Results on May 11
01 Mayo 2023 - 7:00AM
Business Wire
OmniAb, Inc. (Nasdaq: OABI) will report financial results
for the three months ended March 31, 2023 before the open of the
U.S. financial markets on Thursday, May 11, 2023 and will hold a
conference call that same day beginning at 8:30 a.m. Eastern
time.
Conference Call and Webcast Information
What:
OmniAb conference call to discuss
financial results and business updates
Date:
Thursday, May 11, 2023
Time:
8:30 a.m. Eastern time
Conference Call:
U.S. (888) 886-7786
International +1 (416) 764-8658
Conference ID is 36818707
Webcast:
Live and replay webcast of the call with
slides will be available here.
About OmniAb®
OmniAb, Inc.’s discovery platform provides pharmaceutical
industry partners access to diverse antibody repertoires and
high-throughput screening technologies to enable discovery of
next-generation therapeutics. At the heart of the OmniAb platform
is the Biological Intelligence™ (BI) of our proprietary transgenic
animals, including OmniRat®, OmniChicken® and OmniMouse® that have
been genetically modified to generate antibodies with human
sequences to facilitate development of human therapeutic
candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic
chicken) address industry needs for bispecific antibody
applications though a common light chain approach, and OmniTaur™
features unique structural attributes of cow antibodies for complex
targets. We believe the OmniAb animals comprise the most diverse
host systems available in the industry and they are optimally
leveraged through computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms to identify fully human antibodies with superior
performance and developability characteristics. An established core
competency focused on ion channels and transporters further
differentiates our technology and creates opportunities in emerging
target classes. OmniAb antibodies have been leveraged across
modalities, including bispecific antibodies, antibody-drug
conjugates and others. The OmniAb suite of technologies span from
BI-powered repertoire generation to cutting edge antibody discovery
and optimization offering a highly efficient and customizable
end-to-end solution for the growing discovery needs of the global
pharmaceutical industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005010/en/
OmniAb, Inc. Neha Singh investors@OmniAb.com Twitter @OmniAbTech
(510) 768-7760
LHA Investor Relations Yvonne Briggs ybriggs@lhai.com (310)
691-7100
OmniAb (NASDAQ:OABI)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
OmniAb (NASDAQ:OABI)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024